Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to $700000.0.

  • Entrada Therapeutics' Tax Provisions rose 13684.21% to $700000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$929000.0, marking a year-over-year decrease of 10432.66%. This contributed to the annual value of $900000.0 for FY2024, which is 9519.77% down from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Tax Provisions is $700000.0, which was up 13684.21% from $200000.0 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Tax Provisions ranged from a high of $18.7 million in Q4 2023 and a low of -$17.4 million during Q3 2023
  • For the 3-year period, Entrada Therapeutics' Tax Provisions averaged around $2.1 million, with its median value being $1.3 million (2024).
  • Per our database at Business Quant, Entrada Therapeutics' Tax Provisions crashed by 10975.94% in 2024 and then surged by 13684.21% in 2025.
  • Over the past 3 years, Entrada Therapeutics' Tax Provisions (Quarter) stood at $18.7 million in 2023, then plummeted by 109.76% to -$1.8 million in 2024, then surged by 138.27% to $700000.0 in 2025.
  • Its Tax Provisions stands at $700000.0 for Q3 2025, versus $200000.0 for Q2 2025 and -$1.8 million for Q4 2024.